2,5-Bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole

Catalog No. :
ACBDLC865
CAS No. :
1116122-85-0
Molecular Formula :
C26H32B2N2O5
Molecular Weight :
474.17

IUPAC Name:2,5-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole

2,5-Bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$428.00Login to see priceInquiryInquiry
1g95%$1073.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,5-Bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole
IUPAC Name2,5-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole
MDL No.MFCD25460334
Molecular FormulaC26H32B2N2O5
Molecular Weight474.17
SMILESCC1(C)C(C)(C)OB(C2=CC=C(C3=NN=C(C4=CC=C(B5OC(C)(C)C(C)(C)O5)C=C4)O3)C=C2)O1
InChI KeyLGFGAXPLFWYXOI-UHFFFAOYSA-N
Synonym1,3,4-Oxadiazole, 2,5-bis[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]-;2,5-Bis[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,4-oxadiazole
CAS No.1116122-85-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACBDLC865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBDLC865 route product structure diagram
    ACBDLC8651116122-85-0
Inquiry

2. ACBDLC865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVWOM835 route compound structure diagram
    ACVWOM8352096338-52-0 In Stock
  2. Then
  3. ACBDLC865 route product structure diagram
    ACBDLC8651116122-85-0
Inquiry

Comments (0)